日本優先發佈策略：全球專利申請、政策與市場情報決策架構（美國、歐盟五國、日本、中國）

在現代的大部分時期，全球製藥公司將日本視為監管流程中的「二把手」。也就是說，藥物研發在美國或歐洲進行，然後將申請文件交給日本子公司。然而，這種權力平衡如今經常發生逆轉，而且不再是例外，因此需要採取策略性應對措施。衛材（Eisai）首次在日本提交了「Rekenbi」的上市申請。勃林格殷格翰（Boehringer Ingelheim）幾乎獨立地向日本監管機構提交了First-in-Class口服藥物的申請。諾華（Novartis）將「Pulvicto」預計於2025年獲批與在笹山投資建廠結合。像百濟神（BeiGene）這樣的中國公司現在也直接在日本設立機構。多種因素促成了這項措施的合理性。日本藥品和醫療器材管理局（PMDA）的核准速度顯著提升，透過先導藥認定和有條件批准等途徑激勵藥物在日本早期研發，新的價格溢價明確給予在日本早期上市的藥物優惠待遇，以及圍繞「藥品短缺」的政治辯論促使政府積極吸引而非被動等待未獲批准藥物的供應商，這些因素共同構成了「日本優先」政策的真正爭議點。真正的爭議點在於何時「日本優先」才是合適的。現行的定價體系仍然迫使藥物大幅折扣，而隨著市場擴張而進行的重新定價可能會阻礙先導藥溢價旨在獎勵的成長。此外，日本較小的人口規模也可能使全球統計計畫的發展變得複雜。答案取決於核准機制、臨床試驗進行的地區、其他監管機構對亞洲地區受試者的招募要求以及製藥公司的合作選擇。因此，本報告並非旨在得出最終結論，而是旨在提供一個決策架構。而這個框架正是當前情勢下所需要的，因為各種影響因素都在不斷變化。權重會隨著每個定價週期和新藥認證撤回公告的發布而變化。本報告系統性地整理了高階主管實際考慮的因素－審查流程的結構和時間安排、保費和價格調整規則、新藥認證撤回後贊助商招募的趨勢、日本I期臨床試驗的法規、上市許可持有人（MAH）和合作關係結構，以及以日本為基礎的全球發展經濟學。此外，透過對葛蘭素史克（GSK）、勃林格殷格翰（Boehringer）、Guardant Health、施維雅（Servier）、阿斯特捷利康（AstraZeneca）、諾華（Novartis）、百濟神州（BeiGene）、中外製藥（Chugai）、第一三共（Daiichi Sankyo）、武田製藥（Takeda）和衛材（Eisai）的具體案例研究，本報告展示了不同類型的公司如何針對相同的挑戰提出不同的解決方案。本報告將對外國製藥公司策略團隊確定申請順序、在日本建立合作關係的業務拓展團隊以及為日本市場相關資產提供承銷的投資者有所裨益。

調查範圍和目標

本報告涵蓋了日本藥品管理局 (PMDA) 的核准流程和審查速度、國民健康保險 (NHI) 定價獎勵和重新定價風險、藥品損失政策和贊助商招募、臨床試驗設計和目標人群考慮因素、上市許可持有人 (MAH) 和合作結構，以及「日本早期」和「日本優先」戰略的比較案例研究。

報告要點

• 「日本優先」策略背後的政策架構：「先行者制度」、有條件批准和先行者溢價。
• 市場擴張將促使重新定價和 2026 年的改革，這對利潤計算有何影響？
• 針對各類公司的具體案例研究：跨國公司、中型公司、診斷公司和中國公司。
• 全球發展計畫中臨床試驗地理範圍的考量以及在亞洲地區招募受試者的考量。
• 按資產和公司類型分類的「日本優先」評估框架
• 透過合作關係和 MAH（上市許可持有人）制度來降低過早進入日本市場的風險。

目錄

第1章：摘要整理

第2章 日本首航戰略：政策與體制框架

第3章：贖回、定價與資金流動

第4章：服務提供者與營運商的現況：結構與經濟性

第5章：勞動力與能力分析

第6章：技術與供應商生態系統

第7章 國際比較：美國、歐盟五國、中國

第8章：對新進者和投資者的影響

第9章附錄：調查方法與資訊來源

提及的公司

• 葛蘭素史克（英國）—這家跨國公司在日本採取先發優勢策略和新的價格溢價，奉行早期應用策略。
• 勃林格殷格翰（德國）－日本開發機構；為Jardiance​​時代日本經濟樹立了先例。
• 美國液體活體組織切片公司Guardant Health（美國）—美國液體活體組織切片公司，計劃進軍日本市場。診斷證據案例研究。
• 施維雅（法國）—一家中型跨國公司在日本獲得早期癌症治療藥物批准的案例研究。
• 阿斯特捷利康（英國）－擴大在日本的研發基地，以與第一三共的ADC合作為中心。
• 諾華（瑞士）- 日本 - 放射性配體的早期研發：Pulvict 將於 2025 年獲批，並投資笹山工廠
• 百濟神州（CN）—一家起源於中國的全球性公司，透過替Tislelizumab和血液疾病治療藥物在日本拓展企業發展。
• 中外製藥（日本）－羅氏的日本子公司。源自日本的全球擴張標竿。
• 第一三共（日本）－面向日本的DXd ADC的全球首創經濟模式
• 武田製藥（日本）－一家總部位於日本的全球上市公司。在藥品虧損爭議中調整產品組合優先順序。
• 衛材（日本）- Rekenbi Japan - 因政策誘因提前上市（2023年12月）

For most of the modern era, global pharma treated Japan as a filing afterthought: develop in the US and Europe, then hand the dossier to a Japanese affiliate. That hierarchy is now inverted often enough to require a strategy, not an exception. Eisai filed Leqembi in Japan in the first wave. Boehringer Ingelheim took a first-in-class oral drug to Japanese regulators essentially alone. Novartis paired its 2025 Pluvicto approval with factory investment in Sasayama. Chinese-origin companies such as BeiGene now build Japan organizations directly. Several forces converged to make this rational: PMDA review speed has improved markedly; the sakigake designation and conditional-approval routes reward early Japanese development; new pricing premiums explicitly favor drugs launched early in Japan; and the drug-loss political debate has pushed the government to recruit sponsors for unapproved medicines rather than wait for them. What remains genuinely contested is when Japan-first is right. The pricing system still cuts aggressively, market-expansion repricing punishes the very growth a pioneer premium rewards, and small Japanese populations can complicate global statistical plans. The answer is conditional - on mechanism, on trial geography, on Asian-enrollment requirements from other regulators, on the maker's partnering options - which is why this report is built as a decision framework rather than a verdict. A framework is also what the moment demands, because the inputs keep moving: every pricing cycle and every drug-loss announcement shifts the weighting. It assembles the inputs a C-suite actually weighs: review-pathway mechanics and timelines, the premium and repricing rulebook, drug-loss sponsor-recruitment rounds, domestic Phase 1 rules, MAH and partnership structures, and the economics of Japan-anchored global development. It then works through named cases - GSK, Boehringer, Guardant Health, Servier, AstraZeneca, Novartis, BeiGene, Chugai, Daiichi Sankyo, Takeda, and Eisai - showing how different company archetypes resolved the same questions differently. The report serves foreign-pharma strategy teams deciding filing sequences, business-development groups structuring Japan partnerships, and investors underwriting Japan-exposed assets.

Scope and Coverage

The report covers PMDA pathways and review speed, NHI pricing incentives and repricing exposure, drug-loss policy and sponsor recruitment, trial-design and population considerations, MAH and partnering structures, and comparative case studies of Japan-early and Japan-first strategies.

Report Highlights

• The policy stack behind Japan-first logic: sakigake, conditional approval, and pioneer premiums
• How market-expansion repricing and the FY2026 reform change the calculus
• Named case studies across multinational, midsize, diagnostics, and China-origin archetypes
• Trial-geography and Asian-enrollment considerations in global development plans
• A scoring framework for the Japan-first decision by asset and company type
• Partnership and MAH structures that de-risk a Japan-early commitment

Table of Content

1. Executive Summary

2. Japan-First Launch Strategy: Policy and Institutional Framework

3. Reimbursement, Pricing, and Funding Flows

4. Provider and Operator Landscape: Structure and Economics

5. Workforce and Capacity Analysis

6. Technology and Vendor Ecosystem

7. International Comparison: US, EU5, and China

8. Implications for Entrants and Investors

9. Appendix: Methodology and Sources

Companies Mentioned

• GSK (UK) - multinational pursuing Japan-early filing strategies under sakigake and new pricing premiums
• Boehringer Ingelheim (DE) - Japan development organization; Jardiance-era Japan economics precedent
• Guardant Health (US) - US liquid-biopsy company pursuing Japan entry; diagnostics evidence case study
• Servier (FR) - Japan-early oncology approvals as a midsize multinational case
• AstraZeneca (UK) - expanded Japan development footprint anchored by the Daiichi Sankyo ADC alliance
• Novartis (CH) - Japan-early radioligand build-out: Pluvicto approval 2025 and Sasayama facility investment
• BeiGene (CN) - China-origin global player building a Japan presence with tislelizumab and hematology filings
• Chugai (JP) - Roche's Japan arm; benchmark for domestic-origin global launches
• Daiichi Sankyo (JP) - DXd ADC global-first economics from a Japan base
• Takeda (JP) - Japan-headquartered global filer; portfolio prioritization under the drug-loss debate
• Eisai (JP) - Leqembi Japan-early launch (Dec 2023) as a policy-favored case

List of Tables

• Table 1. Historical drug-lag and drug-loss record in Japan: measures and policy responses
• Table 2. PMDA review-time trends for new drug applications, 2015-2026
• Table 3. Sakigake designation system: criteria, benefits, and designated products
• Table 4. Conditional early-approval and time-limited approval routes after the 2025 PMD Act amendments
• Table 5. Pioneer and early-launch pricing premiums: eligibility rules and application practice
• Table 6. Market-expansion repricing mechanics and their interaction with pioneer premiums
• Table 7. FY2026 NHI reform elements affecting launch-sequence economics
• Table 8. MHLW drug-loss sponsor-recruitment rounds: listed products and outcomes
• Table 9. Relaxed Japanese Phase 1 requirements and their use in global programs
• Table 10. PMDA consultation menu and its role in early Japan planning
• Table 11. Asia-region evidence expectations: ICH E5 and E17 in current practice
• Table 12. Japanese-population requirements across major indication areas
• Table 13. Bridging-strategy options for sponsors without Japanese Phase 3 cohorts
• Table 14. MAH, D-MAH, and licensing structures for Japan-early entries
• Table 15. Distributor-versus-affiliate launch models and their economics
• Table 16. GSK's Japan-early filing strategy: program selection and pathway use
• Table 17. Boehringer Ingelheim's solo Japan filing: evidentiary and regulatory structure
• Table 18. Eisai Leqembi Japan launch (2023): policy-favored sequence and execution
• Table 19. Novartis radioligand build-out: Pluvicto approval (2025) and Sasayama investment
• Table 20. AstraZeneca's Japan development expansion anchored by the Daiichi Sankyo alliance
• Table 21. Servier's Japan-early oncology approvals as a midsize multinational model
• Table 22. Guardant Health's Japan entry: diagnostics evidence and sequencing case
• Table 23. BeiGene's direct Japan build-out: tislelizumab and hematology filings
• Table 24. Chugai and Daiichi Sankyo as domestic-origin global-launch benchmarks
• Table 25. Takeda portfolio prioritization under the drug-loss debate
• Table 26. Pricing-outcome comparison across Japan-early and Japan-late launch cases
• Table 27. Trial-recruitment performance of Japanese sites in global programs
• Table 28. PMDA office network and overseas engagement: DC and Bangkok functions
• Table 29. RWD guidance (2026) and its uses in Japan development plans
• Table 30. Pediatric and rare-disease incentives relevant to filing-sequence decisions
• Table 31. Orphan designation practice and its pricing interaction
• Table 32. Comparator-selection expectations in Japan-enrolling pivotal trials
• Table 33. Local medical-affairs and KOL infrastructure requirements for Japan-early launches
• Table 34. Supply, packaging, and labeling lead times for Japan market entry
• Table 35. Post-marketing surveillance obligations and their cost structure
• Table 36. Re-examination-period management for early-launched products
• Table 37. Decision-framework scoring model: asset attributes and weightings
• Table 38. Decision-framework application: small-molecule, biologic, cell-therapy, and radioligand archetypes
• Table 39. Decision-framework application: company archetypes from multinational to pre-commercial biotech
• Table 40. Partnering structures that convert Japan-first economics into shared risk
• Table 41. Scenario grid for pricing-rule evolution through the FY2028 revision
• Table 42. Scenario grid for drug-loss policy expansion or retreat
• Table 43. Risk register for sponsors committing to Japan-early sequences
• Table 44. Risk register for sponsors deferring Japan in a drug-loss policy environment
• Table 45. Stakeholder map: MHLW, PMDA, Chuikyo, industry associations, and patient groups
• Table 46. Benchmarking of Japan against EU member-state launch-sequence incentives
• Table 47. Communication strategy for Japan-first announcements to global investors
• Table 48. Organizational-design options for Japan development leadership
• Table 49. Event watchlist: regulatory, pricing, and policy milestones, 2026-2028
• Table 50. Timeline of Japan launch-policy evolution, 2019-2026

List of Figures

• Figure 1. Drug-lag history and the policy inflection in Japan
• Figure 2. PMDA review-pathway map for new molecular entities
• Figure 3. Sakigake and conditional-approval routes: eligibility flow
• Figure 4. Premium and repricing rulebook schematic for early launches
• Figure 5. Market-expansion repricing interaction with launch-sequence economics
• Figure 6. Drug-loss sponsor-recruitment mechanism
• Figure 7. Japanese Phase 1 rules and global program integration
• Figure 8. Evidence-plan options for sponsors without Japanese pivotal cohorts
• Figure 9. ICH E5/E17 application in current Japan practice
• Figure 10. MAH and partnership structure options for Japan entry
• Figure 11. Distributor-versus-affiliate launch model comparison
• Figure 12. GSK Japan-early strategy anatomy
• Figure 13. Boehringer solo-filing case anatomy
• Figure 14. Leqembi Japan launch sequence as a policy-favored model
• Figure 15. Novartis radioligand Japan build-out map
• Figure 16. AstraZeneca Japan expansion anchored by the Daiichi Sankyo alliance
• Figure 17. Servier midsize-multinational entry model
• Figure 18. Guardant diagnostics-entry sequencing model
• Figure 19. BeiGene direct-build model for Japan
• Figure 20. Chugai and Daiichi Sankyo domestic-origin benchmark paths
• Figure 21. Company-archetype map for Japan filing strategy
• Figure 22. Asset-archetype map for Japan filing strategy
• Figure 23. Trial-geography design options incorporating Japanese sites
• Figure 24. Japanese site performance in global recruitment
• Figure 25. Comparator-selection decision tree for Japan-enrolling trials
• Figure 26. PMDA consultation touchpoints across development
• Figure 27. RWD guidance (2026) applications in Japan programs
• Figure 28. Orphan and pediatric incentive interaction with launch sequence
• Figure 29. Local infrastructure build-out requirements for Japan-early launches
• Figure 30. Supply and labeling critical path for Japan entry
• Figure 31. Post-marketing obligations and re-examination management
• Figure 32. Decision-framework scoring model architecture
• Figure 33. Decision-framework output examples by asset archetype
• Figure 34. Decision-framework output examples by company archetype
• Figure 35. Partnering structures sharing Japan-first risk
• Figure 36. Pricing-rule evolution scenarios toward FY2028
• Figure 37. Drug-loss policy scenarios and their strategy implications
• Figure 38. Risk map for Japan-early commitments
• Figure 39. Risk map for Japan-late sequences under current policy
• Figure 40. Stakeholder influence map across MHLW, PMDA, and Chuikyo
• Figure 41. Japan versus EU launch-sequence incentive benchmark
• Figure 42. Investor-communication approach for Japan-first announcements
• Figure 43. Organizational options for Japan development leadership
• Figure 44. Cost-structure comparison of Japan entry models
• Figure 45. Timeline requirements from global filing to Japan launch
• Figure 46. Checklist for a Japan-first board decision
• Figure 47. Case-study synthesis: common features of Japan-early launch cases
• Figure 48. Key-question tree for strategy teams
• Figure 49. Regulatory, pricing, and policy milestone calendar, 2026-2028
• Figure 50. Japan launch-policy evolution timeline, 2019-2026